Overview of Dr. Stein
Dr. Eytan Stein is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from McGaw Medical Center of Northwestern University and has been in practice 13 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2007 - 2010
- Northwestern University The Feinberg School of MedicineClass of 2007
Certifications & Licensure
- FL State Medical License 2021 - Present
- CT State Medical License 2023 - 2025
- NJ State Medical License 2018 - 2025
- NY State Medical License 2010 - 2025
- NC State Medical License 2020 - 2022
- IL State Medical License 2007 - 2010
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
- A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Start of enrollment: 2014 Jul 16
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Start of enrollment: 2016 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Acute myeloid leukemia management and research in 2025.Hagop M Kantarjian, Courtney D DiNardo, Tapan M Kadia, Naval G Daver, Jessica K Altman
CA. 2024-12-10 - Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.Leora Boussi, Jeetayu Biswas, Omar Abdel-Wahab, Eytan Stein
British Journal of Haematology. 2024-12-01 - 5 citationsGenetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.Hartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, Charles Craddock, Hervé Dombret
Blood. 2024-11-21
Journal Articles
- Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined SignificanceE Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
- Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 Inhibitor EnasidenibEytan Stein, MD, Nature
- Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface MutationsMartin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
- Join now to see all
Abstracts/Posters
- Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion StudyEytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Use of Molecular Medicine to Assess Pretreatment Prognosis of Myeloid DisordersASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Adult Clinical Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibNovember 12th, 2024
- Nearly a Third of Leukemia Patients Saw Remission After Taking Experimental PillMarch 30th, 2023
- Near-Terminal Leukemia Patients in Remission as Experimental Drug Raises HopeMarch 16th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: